Neuropsychiatric disease and treatment · 2026
Clinical Efficacy of Integrated Acupuncture and Moxibustion Therapy Combined with Drugs in the Treatment of Acute Depressive Disorder: Protocol for a Pragmatic Randomized Controlled Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Qian, Liu Yi, Lin Dehui, Wang Shanze, Liang Xuesong, Wu Bingxin, Wan Laisiqi, Liu Yuanyuan, Wang Taishun, Liu Huijun, Lai Leixin, Sun Lu, Fu Wenbin
Аннотация
PURPOSE: Escitalopram oxalate is a first-line pharmacological treatment for acute-phase depressive disorder, but delayed onset and adverse effects may compromise adherence and early treatment response. Adjunctive non-pharmacological therapies are commonly used in clinical practice. This study aims to evaluate the efficacy and safety of integrative acupuncture and moxibustion combined with escitalopram oxalate in patients with moderate depressive disorder during the acute phase.
METHODS: This is a single-center, open-label, pragmatic, randomized clinical trial. A total of 300 participants with moderate depressive disorder will be randomly assigned in a 1:1:1 ratio to three groups: escitalopram oxalate alone, escitalopram oxalate plus repetitive transcranial magnetic stimulation (rTMS), or escitalopram oxalate plus integrative acupuncture and moxibustion (iAM) (100 participants per group). All participants will receive escitalopram oxalate, while adjunctive rTMS will be administered five times weekly for 3 weeks and iAM three times weekly for 6 weeks.
OUTCOME MEASURES: The primary outcome is the Hamilton Depression Rating Scale. Secondary outcomes include liver and kidney function, Stanford Expectations of Treatment Scale, Beck Depression Inventory-II, Generalized Anxiety Disorder-7, Hamilton Anxiety Scale, and Insomnia Severity Index.
CONCLUSION: This trial will assess whether iAM combined with escitalopram oxalate is a feasible, safe, and potentially effective adjunctive treatment for moderate depressive disorder during the acute phase. The findings are expected to provide clinical evidence for the use of iAM in routine depression care.
TRIAL REGISTRATION: ITMCTR2024000380 (International Traditional Medicine Clinical Trial Registry; registered on 05 Sep 2024).
METHODS: This is a single-center, open-label, pragmatic, randomized clinical trial. A total of 300 participants with moderate depressive disorder will be randomly assigned in a 1:1:1 ratio to three groups: escitalopram oxalate alone, escitalopram oxalate plus repetitive transcranial magnetic stimulation (rTMS), or escitalopram oxalate plus integrative acupuncture and moxibustion (iAM) (100 participants per group). All participants will receive escitalopram oxalate, while adjunctive rTMS will be administered five times weekly for 3 weeks and iAM three times weekly for 6 weeks.
OUTCOME MEASURES: The primary outcome is the Hamilton Depression Rating Scale. Secondary outcomes include liver and kidney function, Stanford Expectations of Treatment Scale, Beck Depression Inventory-II, Generalized Anxiety Disorder-7, Hamilton Anxiety Scale, and Insomnia Severity Index.
CONCLUSION: This trial will assess whether iAM combined with escitalopram oxalate is a feasible, safe, and potentially effective adjunctive treatment for moderate depressive disorder during the acute phase. The findings are expected to provide clinical evidence for the use of iAM in routine depression care.
TRIAL REGISTRATION: ITMCTR2024000380 (International Traditional Medicine Clinical Trial Registry; registered on 05 Sep 2024).